BioCentury
ARTICLE | Clinical News

Array reports Phase III OS data for binimetinib plus encorafenib in melanoma

February 9, 2018 4:17 PM UTC

Array BioPharma Inc. (NASDAQ:ARRY) reported that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival (OS) compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial to treat BRAF V600 mutation-positive melanoma. In the 921-patient trial, twice-daily 45 mg binimetinib plus once-daily 450 mg encorafenib led to a median OS of 33.6 months vs. 16.9 months for Zelboraf (HR=0.61, 95% CI: 0.47, 0.79, p<0.001).

The two-part, open-label, international trial enrolled patients with BRAF V600 mutation-positive locally advanced, unresectable or metastatic melanoma and evaluated binimetinib plus encorafenib compared to Zelboraf and encorafenib monotherapy...